Global Opioid Use Disorder Market Size Study & Forecast, by Drug (Naltrexone, Buprenorphine, Methadone) by Route of Administration and Distribution Channel and Regional Forecasts 2025-2035

The Global Opioid Use Disorder Market is valued at approximately USD 5.28 trillion in 2024 and is anticipated to grow with a CAGR of more than 11.70% over the forecast period 2025–2035. Opioid Use Disorder (OUD) represents one of the most complex public health challenges worldwide, prompting healthcare systems to deploy evidence-based medications, advanced intervention protocols, and digitally augmented treatment pathways. OUD therapy involves pharmacological and behavioral approaches intended to reduce cravings, prevent relapse, and restore stability in patients’ lives—while simultaneously strengthening community-level safeguards against opioid misuse. The rapid escalation of opioid dependency rates, alongside intensified healthcare awareness campaigns and expanded coverage for medically assisted treatment, continues to influence the strong growth trajectory of the global OUD treatment market.

The rising prevalence of opioid misuse, coupled with increasing overdose fatalities and chronic reliance on prescription pain medication, has significantly amplified the need for comprehensive OUD treatment solutions. These medications—particularly buprenorphine, methadone, and naltrexone—play a crucial role in stabilizing neurochemical pathways disrupted by prolonged opioid exposure. As governments worldwide introduce more rigorous harm-reduction frameworks, expand rehabilitation infrastructure, and mandate insurance coverage for medication-assisted therapies, the demand for long-term OUD treatments continues to intensify. However, challenges such as limited accessibility in rural regions, clinician shortages, stigmatization, and regulatory restrictions around controlled substances may inhibit faster adoption across developing countries throughout the forecast period.

The detailed segments and sub-segments included in the report are:

By Drug:
• Naltrexone
• Buprenorphine
• Methadone

By Route of Administration:
• Oral
• Parenteral
• Others

By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC

Latin America
• Brazil
• Mexico

Middle East & Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Buprenorphine is expected to dominate the market landscape owing to its favorable safety profile, partial agonist characteristics, and broad adoption in outpatient settings. As treatment providers increasingly shift toward regimens that can be administered in community clinics, telemedicine frameworks, and home-based care environments, buprenorphine has emerged as the most adaptable pharmacotherapy. Its capacity to stabilize patients without inducing excessive sedation or euphoria has driven its widespread use across early intervention programs. Although methadone remains a cornerstone therapy—particularly in high-dependency cases—buprenorphine continues to benefit from regulatory flexibility and broader prescriber eligibility, positioning it as the leading market driver.

Methadone currently leads the global market in terms of revenue contribution, largely attributed to its entrenched use in long-term rehabilitation programs and structured opioid treatment centers. Its powerful full-agonist mechanism delivers strong withdrawal suppression, making it indispensable for severe or chronic dependency cases. Meanwhile, naltrexone has shown significant promise in relapse prevention, particularly among patients who seek non-opioid-based treatment options. While methadone retains dominance due to large patient volumes and established treatment protocols, buprenorphine is projected to grow at the fastest pace owing to its accessibility, patient preference, and integration into digital prescribing ecosystems.

The key regions considered for the Global Opioid Use Disorder Market include Asia Pacific, North America, Europe, Latin America, and the Middle East & Africa. North America dominated the market in 2025, supported by robust healthcare infrastructure, high diagnostic penetration, wide availability of opioid treatment programs, and extensive harm-reduction initiatives implemented through federal and state-level policies. Europe follows with strong adoption of medication-assisted treatment frameworks and stringent public-health oversight. Asia Pacific, however, is expected to emerge as the fastest-growing region over the forecast period due to rising awareness of substance misuse, increasing investments in treatment facilities, government-backed rehabilitation campaigns, and an expanding patient pool across India, China, and Southeast Asia.

Major market players included in this report are:
• Indivior PLC
• Alkermes Plc
• Hikma Pharmaceuticals
• Teva Pharmaceutical Industries
• Pfizer Inc.
• Mallinckrodt Pharmaceuticals
• Camurus AB
• Apotex Inc.
• Sun Pharmaceutical Industries
• Viatris Inc.
• Emergent BioSolutions
• Cipla Ltd
• Novartis AG
• Dr. Reddy’s Laboratories
• Amneal Pharmaceuticals

Global Opioid Use Disorder Market Report Scope:
• Historical Data – 2023, 2024
• Base Year for Estimation – 2024
• Forecast period – 2025–2035
• Report Coverage – Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Regional Scope – North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained above.

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2025 to 2035.
• Annualized revenues and regional-level analysis for each market segment.
• Detailed analysis of the geographical landscape with country-level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of the competitive structure of the market.
• Demand-side and supply-side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions. Show more